Barclays PLC Raises Stake in Iradimed Corporation (NASDAQ:IRMD)

Barclays PLC raised its position in shares of Iradimed Corporation (NASDAQ:IRMD - Free Report) by 113.9% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 23,774 shares of the medical equipment provider's stock after acquiring an additional 12,657 shares during the period. Barclays PLC owned approximately 0.19% of Iradimed worth $1,196,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in the company. Stifel Financial Corp raised its stake in shares of Iradimed by 9.8% during the third quarter. Stifel Financial Corp now owns 24,428 shares of the medical equipment provider's stock valued at $1,229,000 after acquiring an additional 2,174 shares in the last quarter. Jacobs Levy Equity Management Inc. raised its position in shares of Iradimed by 1.9% in the third quarter. Jacobs Levy Equity Management Inc. now owns 24,779 shares of the medical equipment provider's stock worth $1,246,000 after acquiring an additional 472 shares during the period. Walleye Capital LLC purchased a new stake in Iradimed during the 3rd quarter valued at about $361,000. Martingale Asset Management L P increased its stake in shares of Iradimed by 15.4% during the third quarter. Martingale Asset Management L P now owns 12,529 shares of the medical equipment provider's stock worth $630,000 after buying an additional 1,671 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of Iradimed during the 3rd quarter worth about $250,000. Institutional investors own 92.34% of the company's stock.

Insiders Place Their Bets

In related news, CFO John Glenn sold 2,500 shares of Iradimed stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $54.18, for a total transaction of $135,450.00. Following the completion of the transaction, the chief financial officer now directly owns 4,383 shares in the company, valued at $237,470.94. The trade was a 36.32 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 37.10% of the stock is owned by insiders.

Iradimed Stock Up 0.8 %

IRMD traded up $0.42 on Monday, reaching $55.09. The company had a trading volume of 28,235 shares, compared to its average volume of 48,376. The stock has a market capitalization of $697.99 million, a PE ratio of 37.73 and a beta of 0.82. Iradimed Corporation has a 1 year low of $40.18 and a 1 year high of $57.95. The stock has a 50-day moving average price of $53.38 and a 200-day moving average price of $48.86.

Iradimed Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, November 25th. Investors of record on Friday, November 15th were issued a dividend of $0.15 per share. This represents a $0.60 dividend on an annualized basis and a dividend yield of 1.09%. The ex-dividend date of this dividend was Friday, November 15th. Iradimed's dividend payout ratio is currently 41.10%.

Iradimed Company Profile

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories, and disposables and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; MRI compatible patient vital signs monitoring system; and 3600 FMD1 with RALU ferromagnetic detection device.